Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of CD30-Directed Genetically Modified Autologous T-Cells (CD30.CAR-T) in Patients With Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

NCT04526834 is registered in ClinicalTrials.gov with Tessa Therapeutics as lead sponsor.

NCT NCT04526834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04526834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of CD30-Directed Genetically Modified Autologous T-Cells (CD30.CAR-T) in Patients With Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
Lead sponsor
Tessa Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 8, 2021
Completion date
March 31, 2036
Enrollment
21 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, diffuse large b cell lymphoma, extranodal nk/t-cell lymphoma, peripheral t cell lymphoma, primary mediastinal large b-cell lymphoma (pmbcl)